Cantor Fitzgerald lowered the firm’s price target on Health Catalyst (HCAT) to $3 from $4 and keeps a Neutral rating on the shares. There are elements of Health Catalyst’s story that can drive stock appreciation, including new leadership, AI-focused investments, and the market need for applications layer, but these need more time to evolve, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $2 from $3.75 at Stifel
- Health Catalyst price target lowered to $2 from $5 at Canaccord
- Health Catalyst price target lowered to $1.75 from $2.75 at Citi
- Health Catalyst reports Q4 adjusted EPS 8c, consensus 10c
- Health Catalyst sees Q1 revenue $68M-$70M, consensus $74.66M